Communicate the benefits of well- established biologics under price pressure from biosimilars The client’s question Biosimilars are an inevitable force in pharma. We at SKIM understand that the introduction of biosimilars may be a major threat to your brand. One of the challenges for biologics at the end of their patent protection is how to communicate the tangible and/or emotional benefits of the branded product in the face of assumed (and real) price differences with biosimilars. For Thomas, our client at a global pharmaceutical company, we used our expertise in messaging research for consumer goods and pharmaceuticals to help his brand develop counter-biosimilar messaging strategies to delay the uptake for biosimilars. Our approach When conducting counter-biosimilar messaging research,

Join for free to read